Mainz Biomed N.V (MYNZ) EBIT: 2022-2023
Historic EBIT for Mainz Biomed N.V (MYNZ) over the last 2 years, with Dec 2023 value amounting to -$6.6 million.
- Mainz Biomed N.V's EBIT rose 21.44% to -$6.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$26.6 million, marking a year-over-year decrease of 0.76%. This contributed to the annual value of -$18.7 million for FY2024, which is 29.83% up from last year.
- Mainz Biomed N.V's EBIT amounted to -$6.6 million in Q4 2023, which was down 16.84% from -$5.6 million recorded in Q3 2023.
- Over the past 5 years, Mainz Biomed N.V's EBIT peaked at -$5.5 million during Q3 2022, and registered a low of -$8.4 million during Q4 2022.
- In the last 2 years, Mainz Biomed N.V's EBIT had a median value of -$6.5 million in 2023 and averaged -$6.6 million.
- Data for Mainz Biomed N.V's EBIT shows a peak YoY increase of 21.44% (in 2023) and a maximum YoY decrease of 15.20% (in 2023) over the last 5 years.
- Over the past 2 years, Mainz Biomed N.V's EBIT (Quarterly) stood at -$8.4 million in 2022, then rose by 21.44% to -$6.6 million in 2023.
- Its EBIT was -$6.6 million in Q4 2023, compared to -$5.6 million in Q3 2023 and -$7.9 million in Q2 2023.